Evidence map›Paper›PMID 37491532›Full record

ArticleScientific reports2023

Comparative effects of CFTR modulators on phagocytic, metabolic and inflammatory profiles of CF and nonCF macrophages.

Daniel S Aridgides, Diane L Mellinger, Lorraine L Gwilt, Thomas H Hampton, Dallas L Mould, Deborah A Hogan, Alix Ashare

Open access · goldAbstract readComparative Study
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. mSphere · 2026
    Article
  3. bioRxiv : the preprint server for biology · 2025
    Article
  4. Article
  5. Article
  6. Insights on the Pathogenesis ofJournal of clinical medicine · 2025
    Review
  7. Review
  8. Review
  9. Wound repair and immune function in theFrontiers in cellular and infection microbiology · 2025
    Review
  10. Article
  11. Neutrophil elastase activates macrophage calpain as a mechanism for phagocytic failure.American journal of physiology. Lung cellular and molecular physiology · 2025
    Article
  12. Article
  13. Frontiers in immunology · 2024
    Review
  14. Macrophage Dysfunction in Respiratory Disease.Results and problems in cell differentiation · 2024
    Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Daniel S AridgidesSection of Pulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. Daniel.S.Aridgides@hitchcock.org.
Diane L MellingerSection of Pulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
Lorraine L GwiltSection of Pulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
Thomas H HamptonDepartment of Microbiology and Immunology, Dartmouth College, Geisel School of Medicine, Hanover, NH, USA.
Dallas L MouldDepartment of Microbiology and Immunology, Dartmouth College, Geisel School of Medicine, Hanover, NH, USA.
Deborah A HoganDepartment of Microbiology and Immunology, Dartmouth College, Geisel School of Medicine, Hanover, NH, USA.
Alix AshareSection of Pulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
Dartmouth–Hitchcock Medical Center · USDartmouth College · US

Funding

Understanding the role of RNA-binding protein mutations in cancerP20GM113132 · NIGMS · DARTMOUTH COLLEGE · PI MADDEN, DEAN R · 2016 to 2025
$25.9M
Translational Research CoreP30DK117469 · NIDDK · DARTMOUTH COLLEGE · PI DEAN R MADDEN · 2018 to 2026
$13.9M
Regional Hypoxia Impacts the Heterogeneity of Inflammatory Lung DiseaseR01HL122372 · NHLBI · DARTMOUTH-HITCHCOCK CLINIC · PI ASHARE, ALIX · 2015 to 2019
$2.0M
Macrophage Pathogen Interactions in Regional Cystic Fibrosis Lung InflammationK24HL150453 · NHLBI · DARTMOUTH-HITCHCOCK CLINIC · PI ASHARE, ALIX · 2020 to 2024
$542k
NHLBI NIH HHS K24 HL150453NHLBI NIH HHS R01 HL122372NHLBI NIH HHS R01HL122372NIDDK NIH HHS P30 DK117469NIGMS NIH HHS P20 GM113132
6 · The paper itself

Abstract

Macrophage dysfunction has been well-described in Cystic Fibrosis (CF) and may contribute to bacterial persistence in the lung. Whether CF macrophage dysfunction is related directly to Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in macrophages or an indirect consequence of chronic inflammation and mucostasis is a subject of ongoing debate. CFTR modulators that restore CFTR function in epithelial cells improve global CF monocyte inflammatory responses but their direct effects on macrophages are less well understood. To address this knowledge gap, we measured phagocytosis, metabolism, and cytokine expression in response to a classical CF pathogen, Pseudomonas aeruginosa in monocyte-derived macrophages (MDM) isolated from CF F508del homozygous subjects and nonCF controls. Unexpectedly, we found that CFTR modulators enhanced phagocytosis in both CF and nonCF cohorts. CFTR triple modulators also inhibited MDM mitochondrial function, consistent with MDM activation. In contrast to studies in humans where CFTR modulators decreased serum inflammatory cytokine levels, modulators did not alter cytokine secretion in our system. Our studies therefore suggest modulator induced metabolic effects may promote bacterial clearance in both CF and nonCF monocyte-derived macrophages.

Indexed as

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorCytokinesHumansMacrophagesMonocytesMutationCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorCytokines

Identifiers

PMID37491532
PMCPMC10368712
OpenAlexW4385240207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.